Pioneering Biotech Company Athos Deploys NVIDIA HGX H100 GPUs on Vultr
Jun 18, 2024

Athos Therapeutics, Inc., a clinical-stage biotechnology company, is revolutionizing the field of precision small molecule therapeutics for immune-mediated diseases and cancer. Leveraging artificial intelligence, Athos is dedicated to unraveling the complexities of autoimmune and cancer biology through detailed molecular-level analysis.

Athos is driving groundbreaking advancements by pinpointing key hubs within these networks and aligning them with its advanced small-molecule computational and medicinal chemistry platforms. The cornerstone of Athos's innovation is its fully autonomous AI analytical platform, which includes the Athos data lake and a cutting-edge integrative deep machine learning engine.

The challenge: Finding the right cloud provider to support medical breakthroughs

The Athos platform requires reliable access to GPUs to power their sophisticated AI algorithms. In their search for a cloud provider, Athos sought a platform that could offer:

  • Scalable and agile solutions adaptable to hardware upgrades, reducing the risk of limited technical support and escalating long-term costs.
  • A user-friendly interface for seamless interactions with computational resources.
  • Cost efficiency by eliminating the need to build, operate, and maintain their data centers – significantly saving on hardware, utilities, and maintenance expenses.
  • Engineering support and maintenance for hardware failures, driver issues, and software dependency concerns.
  • Disaster recovery capabilities to safeguard data and AI algorithm checkpoints in case of hardware or software failures.
  • Security and confidentiality for intellectual property, omics data, and proprietary AI algorithms.
  • Monitoring and management tools to optimize resources and increase hardware utility rates and efficiencies.

Athos takes flight with Vultr

Athos initially utilized public cloud platforms to train their algorithms. However, they faced high pricing structures and limited engineering support. Athos needed a new cloud solution as their data needs expanded and operations scaled. Through their collaboration with Dell Technologies, Athos was introduced to Vultr. The solution: utilizing NVIDIA HGX H100 GPUs on Vultr Cloud GPU.

"Because our large datasets continue to grow every year, Vultr and Dell's scalable and secure GPU infrastructure enabled us to train such large datasets for precision medicine on autoimmune diseases and cancer," said June Guo, VP of Artificial Intelligence & Machine Learning at Athos. "Besides having reliable access to NVIDIA HGX H100s, the excellent engineer support Vultr provides minimizes downtime and maximizes our productivity."

Athos is committed to providing novel precision therapeutics for patients with autoimmune diseases and cancer. The combination of Vultr Cloud GPU, powered by NVIDIA, and Dell infrastructure enabled us to achieve our aims. We are excited about collaborating with the Athos AI computational team and Vultr,” said Dimitrios Iliopoulos, PhD MBA, President and CEO of Athos.

AI is powering tomorrow’s treatments, helping to aid in drug discovery and development, genomics and precision medicine, and clinical imaging. Vultr Cloud GPU, powered by NVIDIA, brings advanced AI and machine learning capabilities within reach of businesses like Athos, who are at the forefront of the future of medicine.

Ready to elevate your own business? Sign up now for a $200 free credit, and explore how Vultr can propel businesses forward while optimizing costs.